Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging
April 14th, 2011
26.1K views
An experimental mouse model of bone metastasis was established following intracardiac delivery of luciferase expressing mammary tumor cells. Tumor development and resulted osteolytic lesion were monitored longitudinally with bioluminescence and micro CT imaging.
Overview
This study establishes an experimental mouse model of bone metastasis using luciferase-expressing mammary tumor cells delivered via intracardiac injection. Tumor development and osteolytic lesions were monitored using bioluminescence and micro CT imaging techniques.
Key Study Components
Area of Science
- Oncology
- Imaging Techniques
- Bone Metastasis
Background
- Longitudinal imaging is crucial for tracking disease progression in preclinical studies.
- Optical imaging methods provide quantitative data on tumor growth and gene expression.
- Micro CT imaging offers high-resolution anatomical details that complement optical imaging.
- Low radiation doses are essential for minimizing biological effects during imaging.
Purpose of Study
- To monitor tumor metastases and osteolytic lesion development in a mouse model.
- To demonstrate the effectiveness of combining optical imaging with micro CT.
- To validate the intracardiac injection technique for tumor cell delivery.
Methods Used
- Intracardiac injection of luciferase-expressing mammary tumor cells into mice.
- Bioluminescence imaging to monitor tumor cell metastasis.
- Micro CT imaging to assess osteolytic lesions.
- Coregistration of optical and CT images for comprehensive analysis.
Main Results
- Successful monitoring of tumor progression and osteolytic lesions over time.
- Bioluminescence imaging indicated metastases in several mice.
- Micro CT revealed the development of osteolytic lesions associated with tumor growth.
- Coregistered datasets allowed for quantitative analysis of disease progression.
Conclusions
- The combined use of bioluminescence and micro CT imaging provides a robust method for studying bone metastasis.
- This approach enhances the understanding of tumor behavior and osteolytic activity.
- Future studies can leverage this model for therapeutic testing and biological insights.
Frequently Asked Questions
What is the significance of using luciferase-expressing cells?
Luciferase-expressing cells allow for real-time monitoring of tumor growth through bioluminescence imaging.
How does micro CT contribute to this study?
Micro CT provides high-resolution anatomical details that complement the functional data obtained from bioluminescence imaging.
What precautions are taken during the intracardiac injection?
Anesthesia is used, and multiple mice are prepared to account for any unforeseen complications during the injection.
Why is low radiation dose important in imaging?
A low radiation dose minimizes cumulative effects on the biology of the animals, allowing for repeated imaging without adverse effects.
What are the implications of this research?
This research enhances the understanding of bone metastasis and provides a platform for testing new therapies.
Executive Industry Relevance
This multimodal imaging approach enables preclinical oncology teams to simultaneously track tumor burden and osteolytic lesion progression in vivo, providing functional and anatomical readouts critical for de-risking bone metastasis models. By combining bioluminescence with low-dose micro CT, the method supports longitudinal studies without confounding radiation effects, enhancing predictive confidence in target validation and therapeutic efficacy assessments. The coregistration capability facilitates quantitative analysis of disease progression, informing go/no-go decisions in early discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by monitoring metastatic tumor growth and osteolytic activity in a clinically relevant preclinical model.
- Operational Value: Supports biological de-risking through longitudinal, noninvasive tracking of tumor metastasis and bone lesion development.
- Predictive Value: Generates quantitative bioluminescence and bone volume metrics that aid in portfolio triage and mechanism-of-action confirmation.
Screening & Assay Development
- Scientific Value: Prepares validated metastatic bone models for downstream compound screening by establishing baseline tumor and lesion progression profiles.
- Operational Value: Ensures assay standardization and reproducibility through consistent animal positioning via imaging shuttle and automated co-registration workflow.
- Scalability: Enables platform reuse across studies due to low radiation dosing allowing multiple longitudinal imaging sessions per subject.
Translational & Preclinical Research
- Translational Relevance: Models human bone metastasis progression using MDA-MB-231-luc-D3H2LN cells, a clinically aggressive lymph node metastasis-derived line.
- Preclinical Continuity: Bridges discovery and preclinical validation by enabling simultaneous monitoring of tumor growth and osteolytic lesion development over five weeks.
- Risk-Adjusted Advancement: Provides anatomical and functional data to support data-driven decisions on therapeutic candidates targeting bone metastasis pathways.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for bone metastasis-focused oncology programs.
- Discovery Biology: Supports hypothesis testing and pathway clarification by visualizing metastatic dissemination and osteolytic lesion formation in vivo.
- Screening: Delivers assay readiness through standardized, reproducible imaging sessions enabled by the imaging shuttle and low-dose micro CT.
- Analytics: Provides quantitative outputs including bioluminescence signal intensity and bone volume measurements for comparative analysis across conditions.
- Translational Research: Connects to preclinical continuity by modeling osteolytic lesion development in a disease-relevant system over longitudinal timepoints.
- Enterprise Reuse: Positions the imaging workflow as a reusable capability across oncology projects due to non-invasive design and minimal cumulative radiation burden.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by reducing mechanistic ambiguity in bone metastasis models through correlated functional and anatomical data.
- Operational Value: Improves standardization and reproducibility via automated co-registration and consistent animal handling across imaging modalities.
- Strategic Value: Informs better go/no-go decisions by enabling early detection of osteolytic progression, reducing late-stage biological risk in bone-targeted programs.
- Portfolio Impact: Supports risk-adjusted prioritization through quantitative longitudinal tracking of tumor and lesion burden.
Implementation Considerations
- Requires expertise in preclinical imaging, animal handling, and intracardiac injection techniques.
- Dependent on IVIS Spectrum and Quantum FX micro CT systems with Living Image 4.1 software for co-registration.
- Necessitates cross-team standardization between in vivo pharmacology and imaging groups for consistent longitudinal data collection.
- Involves adaptation considerations when applying the model to different cell lines or bone sites beyond femur/tibia.
- Practical limitation: Successful metastatic modeling depends on accurate intracardiac injection, requiring training and animal surplus to account for variability.
Biopharma FAQs
Why does bioluminescence imaging matter for target validation in bone metastasis models?
Bioluminescence imaging enables real-time, quantitative monitoring of tumor cell metastasis in vivo, providing functional readouts that support therapeutic hypothesis testing and target validation in preclinical oncology studies.
How does independent variable isolation fit the discovery pipeline when using intracardiac injection of luciferase-expressing cells?
Isolating the independent variable of tumor cell delivery via intracardiac injection ensures that observed metastatic progression and osteolytic activity are directly attributable to the injected cell line, supporting reliable target validation in discovery workflows.
What quantitative dependent variable measurements enable assessment of osteolytic lesion development in this model?
Bone volume measurements derived from micro CT imaging, particularly in the distal femur and proximal tibia, provide quantitative dependent variables to track osteolytic lesion progression over time in longitudinal studies.
Why do replication requirements matter for cross-functional collaboration in multimodal imaging studies?
Replication requirements ensure consistent animal positioning and imaging parameters across bioluminescence and micro CT sessions, enabling reliable data comparison and cross-functional alignment between pharmacology and imaging teams.
What statistical analysis capabilities are required before implementing coregistered bioluminescence and micro CT data?
Implementation requires statistical capabilities to analyze co-registered datasets, including longitudinal comparison of bioluminescence signal intensity and bone volume metrics to monitor disease progression and therapeutic response.
Chapters in this video
0:05
Title
1:26
Intracardiac Injection of Cells into Animals
2:58
Bioluminescence Imaging to Monitor Metastases
3:56
Longitudinal Monitoring of Osteolytic Lesions Using Micro CT
5:02
3D Co-registration and Analysis of BLI and Micro CT
5:39
Monitoring Tumor Metastases and Osteolytic Lesions after Intracardiac Injection
7:30
Conclusion
